About this Journal Submit a Manuscript Table of Contents
Journal of Allergy
Volume 2012 (2012), Article ID 969861, 2 pages
http://dx.doi.org/10.1155/2012/969861
Letter to the Editor

Comment on “Therapeutic Effects and Biomarkers in Sublingual Immunotherapy: A Review”

Allergy Associates of La Crosse, Ltd., Onalaska, WI 54650, USA

Received 4 May 2012; Accepted 29 May 2012

Copyright © 2012 George F. Kroker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Numerous sublingual immunotherapy studies have shown efficacy using a wide variety of dosing regimens. Despite a few grade III and one anaphylactic reaction due to a patient over-dose, there have been no fatal reactions resulting from sublingual immunotherapy treatment. Although safer than SCIT, SLIT is still immunotherapy. Special consideration should be given to what will ensure the highest level of safety for the patient given his or her history, exam and allergy test results. Dosing levels for sublingual immunotherapy should be based on what is therapeutically effective for each individual patient and adjusted accordingly throughout the treatment course.